Product Description
Alpha Beta iT cell program targeting BCMA in myasthenia gravis, and an undisclosed iT cell focused research program in solid tumors. (Sourced from: https://investors.centurytx.com/news-releases/news-release-details/century-therapeutics-strengthens-position-autoimmune-disease)
Mechanisms of Action: CAR-T,BCMA
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Century Therapeutics
Company Location: PHILADELPHIA PA 19104
Company CEO: Osvaldo Flores
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|